GLI1 polymorphisms influence remission rate and prognosis of young de novo acute myeloid leukemia patients treated with cytarabine-based chemotherapy.

Yanfeng Liu, Yi Liu, Peng Chen, Ge Chen, Xiaoping Chen

Abstract read

In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 91% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Yanfeng LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.

Yi LiuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, 410008, China.

Peng ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.

Ge ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.

Xiaoping ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China. chenxiaoping@csu.edu.cn.

Central South University · CNXiangya Hospital Central South University · CNPharmacoGenetics (China) · CN

Funding

Natural Science Foundation of Hunan Province 2021JJ41011

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy. Cytarabine (Ara-C)-based chemotherapy is the primary treatment for AML, but currently known prognostic risk stratification factors cannot fully explain the individual differences in outcome of patients. In this article, we reported that patients with homozygous GLI1 rs2228224 mutation (AA genotype) had a significantly lower complete remission rate than those with GG wild type (54.17% vs.76.02%, OR = 1.993, 95% CI: 1.062-3.504, P = 0.031). GLI1 rs2229300 T allele carriers had remarkably shorter overall survival (513 vs. 645 days, P = 0.004) and disease-free survival (342 vs. 456 days, P = 0.033) than rs2229300 GG carriers. Rs2229300 G > T variation increased the transcriptional activity of GLI1. CCND1, CD44 and PROM1 were potential target genes differentially regulated by GLI1 rs2229300. Our results demonstrated for the first time that GLI1 polymorphisms influence chemosensitivity and prognosis of young de novo AML patients treated with Ara-C.

Indexed as

CytarabineLeukemia, Myeloid, AcuteRemission InductionZinc Finger Protein GLI1AdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalFemaleHumansMaleMiddle AgedPolymorphism, Single NucleotidePrognosisYoung AdultCytarabineGLI1 protein, humanZinc Finger Protein GLI1Acute myeloid leukemiaCytarabineGlioma-associated oncogene homolog 1HedgehogSingle nucleotide polymorphisms

Identifiers

PMID38676765

DOI10.1080/146532401317248054

OpenAlexW4395694641

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.